• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

How John Fetterman Came Out of the Darkness
When he looks back on the past year—a year in which he nearly died, became a U.S. Senator, and nearly died again—it is the debate that John Fetterman identifies as the ­breaking point. “The debate lit the mitch,” he says, then shakes his head in frustration and tries again. The right word is there in his brain, but he struggles to get it out. “Excuse me, that should be lit the mitch—” He stops and tries again. “Lit the match,” he says finally. Oct. 25, 2022: the date is lodged in his mind. “I knew I had to do it,” he tells me. “I knew that the vote...
Source: TIME: Health - July 20, 2023 Category: Consumer Health News Authors: Molly Ball Tags: Uncategorized Congress Cover Story Exclusive feature uspoliticspolicy Source Type: news

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news